The MHRA has issued advice on the safe use of Gadolinium-containing contrast agents.
The advice supports safer use of gadolinium-containing contrast agents in light of the serious and life-threatening risk of the condition, nephrogenic systemic fibrosis in some patients. Download the MHRA update.
For information on all radiography-related safety information, visit the MHRA's dedicated web page.
